^
    2years
    Engineered toxin body targeting TIGIT depletes Tregs in the tumor microenvironment and reduces tumor burden in mice (SITC 2022)
    6 Here, we demonstrate the efficacy and pharmacodynamic (PD) effects of TIGIT ETB in a hTIGIT/PD-1 expressing humanized mouse model...Conclusions These data demonstrate that targeting TIGIT using our Engineered Toxin Body platform promotes tumor regression through elimination of TIGIT/PD-1 co-expressing immune cells within the TME. Our data supports using ETB as a monotherapy to target TIGIT and represents a wholly novel approach for modulating TIGIT within the TME.
    Preclinical
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • PVR (PVR Cell Adhesion Molecule)
    |
    PD-1 expression • TIGIT overexpression
    |
    Undisclosed TIGIT ETB